Futuresearch Trials

Dallas, Texas 75231

0 studies enrolling now · 16 studies all time

What they study most

ADHD, ADHD - Combined Type, Alzheimer's Disease, Attention Deficit Disorder With Hyperactivity, Attention Deficit Hyper Activity, Attention Deficit Hyperactivity Disorder, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity, Bipolar Depression, Bipolar Disorder, Depression, Depressive Disorder

Studies at this site

• Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301 — Completed
• Feasibility and ML Training Investigation of the Senseye DT for Diagnosis of Adults with PTSD — Completed
• Medibio DDA Confirmatory Performance Study — Completed
• A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine — Completed
• A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania — Completed
• Software Treatment for Actively Reducing Severity of ADHD in Adults (STARS ADHD Adult) — Completed
• A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder — Completed
• An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine — Completed
• Software Treatment for Actively Reducing Severity of ADHD — Completed
• Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study — Completed
• A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease — Stopped early
• Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD) — Completed
• A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD) — Completed
• Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression — Completed
• Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 — Completed
• Switching to Iloperidone From Other Antipsychotics in Schizophrenia — Completed